US › Healthcare

Immix Biopharma Inc (IMMX)

US · Healthcare · Biotechnology

$9.33+10.81%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-10.1M
Profit YoY
-122.1%
EPS
$-0.18
EPS estimate
$-0.21

EPS came in at -0.18 against a street estimate of -0.21 — a beat of 14.3%.

Key statistics

Market cap
$599.4M
Forward P/E
0.0
P/B
7.03
Book value
$1.59
EPS (TTM)
$-0.92
52-week high
$12.14
52-week low
$1.94
50-day MA
$9.30
200-day MA
$7.40
Beta
0.11

Analyst view

Analysts rate Immix Biopharma Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $19.91.

Shareholding

Insiders
17.56%
Institutions
45.81%

Largest institutional holders

FundStake
HHG PLC6.75%
Saturn V Capital Management LLC5.19%
Eventide Asset Management, LLC3.58%
Vanguard Capital Management, LLC2.51%
Millennium Management LLC2.46%
Marshall Wace Asset Management Ltd2.31%
Logos Global Management LP1.72%
Vanguard Group Inc1.54%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Immix Biopharma Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.